Annovis Bio Inc (ANVS)
6.55
+0.55
(+9.17%)
USD |
NYSE |
May 31, 16:00
6.525
-0.02
(-0.38%)
Pre-Market: 20:00
Annovis Bio Research and Development Expense (Annual): 38.79M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 38.79M |
| December 31, 2022 | 16.52M |
| December 31, 2021 | 8.479M |
| December 31, 2020 | 3.054M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.7763M |
| December 31, 2018 | 0.1116M |
| December 31, 2017 | 0.2734M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
0.7763M
Minimum
2019
38.79M
Maximum
2023
13.52M
Average
8.479M
Median
2021
Research and Development Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 34.29M |
| Ligand Pharmaceuticals Inc | 24.54M |
| FibroGen Inc | 282.86M |
| SINTX Technologies Inc | 8.713M |
| Stereotaxis Inc | 10.27M |